Xenon Pharmaceuticals (XENE) Total Liabilities (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Total Liabilities data on file, last reported at $49.0 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $49.0 million, up 24.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $49.0 million (up 24.59% YoY), and the FY2025 annual result was $51.4 million, up 18.89% from the prior year.
• Total Liabilities eased to $49.0 million in Q1 2026 per XENE's latest filing, from $51.4 million in the prior quarter.
• Over five years, Total Liabilities peaked at $51.4 million in Q4 2025 and troughed at $16.2 million in Q1 2022.
• A 5-year average of $36.3 million and a median of $38.1 million in 2024 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2023 and 2024: Total Liabilities surged 103.16% in 2023, then fell 4.86% in 2024.
• A 5-year view of Total Liabilities shows it stood at $32.6 million in 2022, then rose by 12.95% to $36.9 million in 2023, then advanced by 17.24% to $43.2 million in 2024, then increased by 18.89% to $51.4 million in 2025, then dropped by 4.69% to $49.0 million in 2026.
• Business Quant data shows XENE's Total Liabilities at $49.0 million in Q1 2026, $51.4 million in Q4 2025, and $48.3 million in Q3 2025.